Final answer:
The EMPA-REG Outcomes trial found that Jardiance significantly reduced the risk of cardiovascular death, heart failure hospitalization, and overall mortality in type 2 diabetes patients with cardiovascular disease.
Step-by-step explanation:
In the EMPA-REG Outcomes trial, Jardiance significantly reduced the risk of cardiovascular death, heart failure hospitalization, and overall mortality in adults with type 2 diabetes and established cardiovascular disease. The results of this trial highlight the importance of managing cardiovascular risk in patients with type 2 diabetes, and how these negative outcomes can sometimes be prevented with lifestyle changes and medications. Jardiance does not have the negative side effects listed in option C, which are associated with some other treatments.